Drug delivery into the brain using poly(lactide-co-glycolide) microspheres

Expert Opinion on Drug Delivery

Volumn 2, Issue 2, 2005, Pages 363-376

  Menei, Philippe ^a   Montero Menei, Claudia ^a   Venier, Marie Claire ^a,b   Benoit, Jean Pierre ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Brain tumour; Cell therapy; Chemotherapy; Drug delivery; Microspheres; Neurotrophic factors; PLGA; Polymer; Stereotaxy

Indexed keywords

ANTIMETABOLITE; BROMOCRIPTINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTOKINE; DOPAMINE; DOXORUBICIN; FLUOROURACIL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GONADORELIN DERIVATIVE; GROWTH FACTOR; IDOXURIDINE; LEVODOPA; MICROSPHERE; MITOMYCIN; NERVE GROWTH FACTOR; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; NIMUSTINE; NORADRENALIN; OXIDOPAMINE; PLACEBO; PLATINUM DERIVATIVE; POLY(METHYL METHACRYLATE); POLYGLACTIN; POLYMER; STEROID; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN EDEMA; BRAIN REGION; BRAIN TISSUE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DEGENERATIVE DISEASE; DEPRESSION; DEVICE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; GLIOBLASTOMA; HALLUCINATION; HUMAN; IMPLANT; IMPLANTATION; INFECTION; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RISK ASSESSMENT; SEXUAL DYSFUNCTION; STEREOTAXIC SURGERY; SURGICAL TECHNIQUE; SYSTEMIC DISEASE; TISSUE INJURY; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOCOMPATIBLE MATERIALS; BRAIN; CELL TRANSPLANTATION; CLINICAL TRIALS; DOPAMINE; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FLUOROURACIL; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTORS; GLIOMA; HUMANS; MICROSPHERES; NERVE GROWTH FACTOR; NEURODEGENERATIVE DISEASES; POLYGLACTIN 910; STEREOTAXIC TECHNIQUES;

EID: 23644435297     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.2.363     Document Type: Article

References (81)

1. KORDOWER JH, PALFI S, CHEN EY et al.: Clinicopathological finding following intraventricular glial-derived neurotrophic factor treatment. Ann. Neurol. (1999) 46:419-424.
2. FOLKMAN J, LONG DM: The use of silicone rubber as a carrier for prolonged drug therapy. J. Surg. Res. (1964) 4:139-142.
3. MAYBERG M, LANGER R, ZERVAS N, MOSKOWITZ M: Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science (1981) 213:228-230.
4. ODA Y, UCHIDA Y, MURATA T et al.: Treatment of brain tumors with anticancer pellet. Experimental and clinical study. No Shinkei Geka (1982) 10:375-381.
5. KUBO O, HIMURO H, INOUE N et al.: Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites. No Shinkei Geka (1986) 14:1189-1195.
6. KUBO O, TAJIKA Y, MURAGAKI Y et al.: Local chemotherapy with slowly-releasing anticancer drug-polymers for malignant brain tumors. J. Control. Rel. (1994) 32:1-8.
7. BREM H, PIANTADOSI S, BURGER PC et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet (1995) 345:1008-1012.
8. WESTPHAL M, HILT DC, BORTEY E et al.: A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol. (2003) 5:79-88.
9. OHYE C: The idea of stereotaxy toward minimally invasive neurosurgery. Stereotact. Funct. Neurosurg. (2000) 74(3-4):185-193.
10. FRIES G, PERNECZKY A: Intracranial endoscopy. Adv. Tech. Stand Neurosurg. (1999) 25:21-60.
11. MENEI P, BENOIT J, BOISDRONCELLE M, FOURNIER D, MERCIER P, GUY G: Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery (1994) 34:1058-1064.
12. DONBROW M: Microcapsules and Nanoparticles in Medicine and Pharmacy. CRC Press Incorporation, Boca Raton, USA (1992).
13. BENOIT J, MARCHAIS H, ROLLAND HYANDE VELDE V: Biodegradable microspheres: advances in production technology. In: Microencapsulation. Methods and Industrial Applications. S Benita (Ed.), Marcel Dekker Incorporation, New York, USA (1996):35-72.
14. LI S: Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J. Biomed. Mater. Res. (1999) 48:342-353.
15. CHASIN M, LEWIS D, LANGER R: Polyanhydrides for controlled drug delivery. Biopharm. Manufactoring (1988) 1:33-46.
16. LEONG KW, BROTT BC, LANGER R: Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J. Biomed. Mater. Res. (1985) 19:941-955.
17. LEONG KW, D'AMORE P, MARLETTA M, LANGER R: Bioerodible polyanhydrides as drug carrier matrices. II: Biocompatibility and chemical reactivity. J. Biomed. Mater. Res. (1986) 20:51-64.
18. FAISANT N, SIEPMANN J, OURY C et al.: The effect of gamma-irradiation on drug release from bioerodible microparticles: a quantitative treatment. Inter. J. Pharmaceutics (2002) 242(1-2):281.
19. FAISANT N, SIEPMANN J, RICHARD J, BENOIT JP: Mathematical modeling of drug release from bioerodible microparticles: effect of γ-irradiation. Eur. J. Pharm. Biopharm. (2003) 56(2):271-279.
20. SPENLEHAUER G, VERT M, BENOIT JP, BODDAERT A: In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials (1989) 10:557-563.
21. FRAZZA EJ, SCHMIDT EE: A new absorbable suture. J. Biomed. Mater. Res. (1971) 5:43-58.
22. VISSCHER GE, ROBINSON RL, MAULDING HV, FONG JW, PEARSON JE, ARGENTIERI GJ: Biodegradation of and tissue reaction to 50:50 poly (DL-lactide-co-glycolide) microcapsules. J. Biomed. Mater. Res. (1985) 19:349-365.
23. MENEI P, DANIEL V, MONTERO-MENEI C, BROUILLARD M, POUPLARD-BARTHELAIX A, BENOIT JP: Biodegradation and brain tissue reaction to poly(D-L lactide-co-glycolide) microspheres. Biomaterials (1993) 14:470-478.
24. VEZIERS J, LESOURD M, JOLLIVET C, MONTERO-MENEI C, BENOIT JP, MENEI P: Analysis of brain biocompatibility of drug-releasing biodegradable microspheres by scanning and transmission electron microscopy. J. Neurosurg. (2001) 95: 489-494.
25. KOU JH, EMMETT C, SHEN P et al.: Bioerosion and biocompatibility of poly(D,L-lactic-co-glycolic acid) implants in brain. J. Control. Release (1997) 43:123-130.
26. GAUTIER SE, OUDEGA M, FRAGOSO M et al.: Poly(alpha-hydroxyacids) for application in the spinal cord: resorbability and biocompatibility with adult rat Schwann cells and spinal cord. J. Biomed. Mater. Res. (1998) 42(4):642-654.
27. EMERICH DF, TRACY MA, WARD KL et al.: Biocompatibility of poly(DL-lactide-co-glycolide) microspheres implanted into the brain. Cell transplant. (1999) 8:47-58.
28. NICHOLAS AP, MCINNIS C, GUPTA KB et al.: The fate of biodegradable microspheres injected into rat brain. Neurosci. Lett. (2002) 323:85-88.
29. FINE, HA, DERAR KB, LOEFFLER JS, BLACK PM, CANELLOS JP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer (1993) 71(8):2585-2597.
30. BURGER PC, DUBOIS PJ, SCHOLD SC et al.: Computerized tomographic and pathologic studies of the untreated, quiescent and recurrent glioblastoma multiforme. J. Neurosurg. (1983) 58:159-169.
31. HOCHBERG FH, PRUITT A: Assumptions in the radiotherapy of glioblastoma. Neurology (1980) 30:907-911.
32. PAINBENI T, VENIER-JULIENNE MC, BENOIT JP: Internal morphology of poly(D, L-lactide-co-glycolide) BCNU-loaded microspheres. Influence on drug stability. Eur. J. Pharmaceutics and Biopharmaceutics (1998) 45:31-39.
33. TORRES AI, BOISDRON-CELLE M, BENOIT JP: Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure. J. Microencapsul. (1996) 13:41-51.
34. EMERICH DF, WINN SR, HU Y et al.: Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors. Pharmaceutical Res. (2000) 17:767-775.
35. EMERICH DF, WINN SR, SNODGRASS P et al.: Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors. Pharmaceutical Res. (2000) 17:776-781.
36. EMERICH FD, WINN SR, BARTUS RT et al.: Injection of chemotherapeutic microspheres and glioma: IV Eradicating tumors in rats. Cell Transplant. (2002) 11:47-54.
37. CHEN W, LU DR: Carboplatin-loaded PLGA microspheres for intracerebral injection: formulation and characterization. J. Microencapsul. (1999) 16(5):551-563.
38. LAGARCE F, CRUAUD O, DEUSCHEL C, BAYSSAS M, GRIFFON-ETIENNE G, BENOIT JP: Oxaliplatin loaded PLAGA microspheres: design of specific release profiles. Inter. J. Pharmaceutics (2002) 242(1-2):243.
39. EMERICH DF, WINN SR, BARTUS RT: Injection of chemotherapeutic microspheres and glioma III: parameters to optimize efficacy. Cell Transplant. (2002) 11:35-45.
40. 125IudR loaded biodegrable microspheres for controlled delivery to the brain. J. Microencapsul. (1998) 15:789-801.
41. GEZE A, VENIER-JULIENNE MC, SAULNIER P et al.: Modulated release of IdUrd from Poly(D, L-lactide-co-glycolide) microspheres by addition of poly(D, L-lactide) oligomers. J. Control Release (1999) 58:311-322.
42. GEZE A, CHOURPA I, BOURY F, BENOIT JP, DUBOIS P: Direct qualitative and quantitative characterization of a radiosensitizer 5-iodo-2′-deoxyuridine within biodegradable polymeric microspheres by FT-Raman spectroscopy. Analyst (1999) 124:37-42.
43. GEZE A, VENIER-JULIENNE MC, MATTHIEU D, PHAN-TAN-LUU R, FILMON R, BENOIT JP: Development of 5-iodo-2′-deoxyuridine milling process to reduce initial burst release from PLGA microparticles. Int. J. Pharm. (1999) 178:257-268.
44. LAWRENCE TS, MAYBAUM J: Fluoropyrimidines as radiation sensitizers. Semin. Radiat. Oncol. (1993) 3:20-28.
45. BOISDRON-CELLE M, MENEI P, BENOIT JP: Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J. Pharm. Pharmacol. (1995) 47:108-114.
46. MENEI P, BOISDRON-CELLE M, CROUÉ A, GUY G, BENOIT JP: Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery (1996) 39:117-124.
47. 3H]-fluorouracil-loaded PLGA microspheres. Eur. J. Pharm. Biopharm. (2002) 53:293-299.
48. ROULIN VG, LEMAIRE L, NENIER-JULIENNE MC, FAISANT N, FEANCONI F, BENOIT JP: Release kinetics of 5-fluorouracil-loaded microspheres on an experimental rat glioma. Anti-Cancer Res. (2003) 23:21-25.
49. LEMAIRE L, MCSHEEHY PMJ, GRIFFITHS JR: Pre-treatment energy status of primary rat tumours as the best predicator of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo. Cancer Chemoth. Pharm. (1998) 42:201-209.
50. ROULIN VG, MEGE M, LEMAIRE L et al.: Influence of 5-fluorouracil-loaded microspheres formulation on efficient rat glioma sensitization. Pharm. Res. (2004) 21:1558-1563.
51. MENEI P, VENIER-JULIENNE MC, GAMELIN E et al.: Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for radiosensibilisation of glioblastoma: pilot study. Cancer (1999) 86:325-330.
52. MENEI P, CAPELLE L, GUYOTAT J et al.: Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized Phase II trial. Neurosurgery (2005) 56(2):242-248.
53. MENEI P, JADAUD E, FAISANT N et al.: Stereotaxic implantation of 5-FU-releasing microspheres in malignant glioma. Cancer (2004) 100:405-410.
54. RHINES D, SAMPATH P, DIMECO F et al.: Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery (2003) 52:872-879.
55. MCRAE-DEGUEURCE A, HJORTH S, DILLON DL, MASON DW, TICE TR: Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue. Neurosci. Lett. (1988) 92:303-309.
56. MCRAE A, HJORTH S, MASSON DW, DILLON DL, TICE TR: Micropencapsulated dopamine (DA) - induced restitution of function in 6-OHDA denervated rat striatum in vivo: comparison between two microsphere excipients. J. Neural Transplant. Plast. (1991) 2:165-173.
57. MCRAE A, DAHLSTRÖM A: Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striatum of rats with 6-OH-DA induced parkinsonism. Neurochem. Int. (1994) 25:27-33.
58. MCRAE A, LING EA, HJORTH S, DAHLSTROM A, MASON D, TICE T: Catecholamine-containing biodegradable microsphere implants as a novel approach in the treatment of CNS neurodegenerative disease. A review of experimental studies in DA-lesioned rats. Mol. Neurobiol. (1994) 9:191-205.
59. ROSENBLAD C: Growth Factor treatment of neurodegenerative disorders: new developments pave the way for clinical success. Idrugs (2004) 7(3):243-248.
60. GILL SS, PATEL NK, HOTTON GR et al.: Direct brain infusion of glial cell-line-derived neurotrophic factor in Parkinson's disease. Nat. Med. (2003) 9:589-595
61. PEAN JM, VENIER-JULIENNE MC, BOURY F, MENEI P, DENIZOT B, BENOIT JP: NGF release from poly(DL(lactide-co-glycolide) microspheres. Effect of some formulation parameters on ancapsulated NGF stability. J. Control. Release (1998) 56:175-187.
62. PEAN JM, VENIER MC, FILMON R, SERGENT M, PHAN-TAN-LUU R, BENOIT JP: Optimization of HSA and NGF encapsulation yields in PLGA microparticles. Int. J. Pharmceutics (1998) 166:105-115.
63. PEAN JM, BOURY F, VENIER-JULIENNE MC, MENEI P, PROUST J, BENOIT J: Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharmaceutical Res. (1999) 16(8):1294-1299.
64. CAMARATA PJ, SURYANARAYANAN R, TURNER DA, PARKER RG, EBNER TJ: Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery (1992) 30:313-319.
65. MENDEZ A, CAMARATA PJ, SURYANARAYANAN R, EBNER TJ: Sustained intracerebral delivery of nerve growth factor with biodegradable polymer microspheres. Methods Neurosci. (1994) 21:150-167.
66. SALTZMAN WM, MAK MW, MAHONEY MJ, DUENAS ET, CLELAND JL: Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems. Pharm. Res. (1999) 16:232-240.
67. PEAN JM, MENEI P, MOREL O, MONTERO-MENEI C, BENOIT JP: Intraseptal implantation of NGF releasing-microspheres promote the long term survival of axotomized cholinergic neurons. Biomaterials (2000) 21:2097-2101.
68. MAYSINGER D, FILIPOVIC-GRCIC J, CUELLO AC: Effects of coencapsulated NGF and GM1 in rats with cortical lesions. NeuroReport (1993) 4:971-974.
69. MENEI P, PEAN JM, NERRIÈRE-DAGUIN V, JOLLIVET C, BRACHET P, BENOIT JP: Intrastriatal NGF-releasing biodegradable microspheres prevent the degeneration of cholinergic and non cholinergic striatal neurons in a model of Huntington's disease. Exp. Neurol. (2000) 161:259-272.
70. GOUHIER C, CHALON S, VENIER-JULIENNE MC et al.: Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurons in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide. Neurosci Lett. (2000) 288(1):71-75.
71. JOLLIVET C, MONTERO-MENEI CN, VENIER-JULIENNE MC, SAPIN A, BENOIT JF, MENEI P: Striatal TH immunoreactive neurons are induced by L-dopa and NGF treatment in 6-OHDA lesioned rats. Neurosci. Letters (2004) 362:79-82.
72. AUBERT-POUESSEL A, VENIER-JULIENNE MC, CLAVREUL A et al.: In vitro study of GDNF release from biodegradable PLGA microspheres. J. Control. Release (2004) 95(3):463-475.
73. GOUHIER C, CHALON S, AUBERT-POUESSEL A et al.: Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse (2002) 44(3):124-131.
74. JOLLIVET C, AUBERT-POUESSEL A, CLAVREUL A et al.: Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials (2004) 25(5):933-942.
75. JOLLIVET C, AUBERT-POUESSEL A, CLAVREUL A et al.:Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease. Neurosci. Lett. (2004) 356(3):207-210.
76. TATARD VM, VENIER JULIENNE MC, BENOIT JP, MENEI P, MONTERO-MENEI CM: In vivo evaluation of pharmacologically active microcarriers releasing NGF and conveying PC12 cells. Cell transplantation (In press).
77. NEWMAN KD, MCBURNEY MW: Poly(DL lactic-co-glycolic acid) microspheres as biodegradable microcarriers for pluripotent stem cells. Biomaterials (2004) 25:5763-5771.
78. LECORRE P, ESTEBE JP, CHEVANNE F, MADELLANT Y, LE VERGE R: Spinal controlled delivery of buvicaine from DL-lactic acid oligomer. J. Pharm. Sci (1995) 84:75-78
79. ESTEBE JP, LE CORRE P, MADELLANT Y, CHEVANNE F, LE VERGE R: Prolongation of spinal anesthesia with buvicaine-loaded (DL-lactide) microspheres. Anesth. Analg. (1995) 81:99-103
80. LAGARCE F, BENOIT JP: Sustained release formulations for spinal drug delivery. J. Drug. Del. Sci. Tech. (2004) 14:331-343.
81. LAGARCE F, RENAUD P, FAISANT N et al.: Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. Eur. J. Pharm. Biopharm. (In press).